The Lowdown on Cancer focuses on the impact of cancer on lives and on the things that give us hope. From the pain of learning you have cancer to innovative new treatments offered by the best and brightest, we’ll give you the Lowdown.
Yes, cancer sucks. But you are not alone. And we are not without hope!
Over the past weeks, we've introduced four additional innovators at the forefront of cancer: ONCO-LIQ - Cancer detection through routine blood testing TELEXOS - Improved cancer diagnostics through detection of circulating tumor cells in blood BETAGLUE -...
"We know that 50% of humans will have cancer at some time in their life." Well if that wasn't enough of a gut punch, wait for this statistic: Of those people with cancer, 50% will be diagnosed with advanced tumors. Which means treatment options may be...
Meet Telexos GmbH. Telexos develops products for the clinical cancer research market and for the personalized cancer diagnostics market. Their focus is on the detection and analysis of rare cells in the blood, in particular circulating tumor cells (CTCs)...
We scoured the globe to bring you this latest innovator! Meet BetaGlue Technologies, a global team of medical industry professionals developing a new technology in the loco-regional therapy of solid tumors. And while it may sound like the stuff of sci-fi...
1 in 5 Americans are at increased risk for hereditary or genetic risk of developing cancer. But most don't even realize it. Sure, we've all filled out those family history forms at the doctor's office. But how well informed were you about your family...
In 2021, an estimated 323,840 new cases of breast cancer are expected to be diagnosed in men and women in the U.S. alone. Approximately 43% of those cases will choose surgical breast reconstruction. Although nipple-sparing surgeries (leaving the...
Our latest innovator bucks the trend, as a "for-profit, social impact, health tech startup." The cancer journey is overwhelming for patients and caregivers. And while many people struggle to advocate for themselves and their loved ones after a cancer...
We've shared some gut-wrenching stories as part of "Save Second Base," our series on breast cancer. But now we share some glimmers of hope. CANCER FUND is more than hope. Through investing in innovation, we bring diagnostics, treatments, and solutions to...
Join us for this special update from Reglagene, the first company in CANCER FUND's portfolio of investments. Reglagene is working to develop targeted cancer therapies, delivered via oral medication, that control cancer cells' ability to become...
Research is only the first step when it comes to cancer innovations. But there are many more stops along the journey from lab to patient. And the catalyst behind it all? Funding, of course! Meet Jon Mengel from CANCER FUND, as he discusses the nearly 150...
As we wrap up our latest series, “Measure Twice, Cut Once: Diagnostics and Monitoring,” let’s take a look back at the four innovators who joined us to share about their innovative technologies.
Stress, cortisol, cancer, and YOU. Meet Jeff Rea of Cormometer, an exciting innovation that puts the patient in the driver seat when it comes to monitoring hormonal stress that can impact cancer treatment and overall wellness....
The most common type of cancer is breast cancer, with 279,100 new cases in the United States in 2020. But there is still so much work to be done to properly diagnosis breast cancer early to save lives and provide less invasive treatments. Jayne Shaw,...
Meet Innovator #2 of our "Diagnostics & Monitoring" series, Joe Camaratta, CEO of Quantitative Radiology Solutions. Joe has pivoted his 30 year background in medical imaging and healthcare IT to focus on bringing ideas out of academia and to market....
Meet biomedical engineer Aaron Weinroth as he discusses SWAN Cytologics and their "elegant solution" to the "inadequacy, inefficiency, and trauma" of traditional needle biopsies. https://youtu.be/gOkNGBP9dak
Meet Greg O'Ryan Johnson, Venture Scout Associate. In his role at the CANCER FUND, Greg contributes by evaluating early stage companies through due diligence and analytical processes. Greg’s mission while at the CANCER FUND is to help entrepreneurs bring...
The innovators we speak with all have one major thing in common - yes, they're part of the fight against cancer, but more pressing is that the only road to the finish line requires FUNDING. That's why CANCER FUND was formed. We invest in cancer...
Thank you for joining us on the journey to explore cancer recurrence in our series “The Bitch Is Back.” Cancer recurrence rates vary widely depending on the type of cancer and other factors, but occurs in roughly 70% of cancer patients, with higher rates...
Tune in for a quick recap of our four innovators as they explain the products their teams are working on to battle cancer recurrence. https://youtu.be/Jl4UiXnrQ_M
Meet Richard Austin, CEO/President of Reglagene, a company out to discover and develop low-cost and noninvasive therapeutic solutions that regain control of genes exploited by cancer to keep patients responsive to treatment....
Meet David Lu, a research scientist at the Yale Cancer Biology Institute and co-founder of Celestra Life Science. Learn about David and his team at Celestra, where they are combining innovations in synthetic lethality and nanotechnology to develop a new...
Meet Darren Cunningham, CEO of Inflection BioSciences, an early-stage drug development company focused on discovering and developing innovative small molecule therapeutics to treat cancer and cancer recurrences. https://youtu.be/26GsLg7uj9o
In our latest series, “The Bitch Is Back,” we have heard from community members about “The Problem,” their struggles with cancer recurrence. We’ve heard from the expert, Dr. Rachna Shroff, to better understand how cancer recurrence happens and how...
The Lowdown wants to change researchers name to . . . https://youtu.be/bRMqsrSOhAY
Cancer is a sneaky bastard! Listen to Dr. Richard Austin give some perspective on curing cancer https://youtu.be/Z1YmyLlRvbQ
We can't understand everything. Stop them and ask questions. It's ok. https://youtu.be/AEzBUjf2Wo4
Everyone is different, don't use others' treatment and side effects as the norm. You are your own person. You will have a different path then the next person or the people before you. https://youtu.be/cr_0bln9jXE
Ann is joined by James Bates, CEO of the healthcare automation innovation known as AdviNow Medical. Listen in as he shares the exciting changes that artificial intelligence brings to the future of healthcare. https://youtu.be/M-7hCKTfpDM
What is the “Valley of Death” and how do companies get over it? https://youtu.be/sg3LNCSlEAo
*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.
*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.
*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.
*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.
*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.
*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.